Last reviewed · How we verify
Mesenchymal stem cell injection
At a glance
| Generic name | Mesenchymal stem cell injection |
|---|---|
| Also known as | Cellgram-ED, MSC, umbilical cord derived MSCs, Lungcellgram, ADR-001 |
| Sponsor | Man Clinic for Andrology, Male Infertility and Sexual Dysfunction |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Back pain
- Arthralgia
- Procedural pain
- Headache
- Nausea
- Ventricular tachycardia
- Pain in extremity
- Fall
- Dyspnoea
- Cardiac failure chronic
- Fatigue
- Cardiac failure congestive
Key clinical trials
- A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD (NA)
- Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments (PHASE2)
- Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss (PHASE1, PHASE2)
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
- Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure (PHASE3)
- Autologous SVF Therapy for Type 2 Diabetes (NA)
- Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: